Skip to content

Key statistics

JCY Bio in numbers.

Every number on this page traces to a single, defendable source. We avoid composite or unverifiable claims.

Platform

Strains, facility and IP

300+

Reserved functional strains

Internal library

>1,000 m²

Laboratory floor area

P2 + GMP facility

80%

Researcher share of headcount

Company composition

100+

IP assets

Strain registrations + patent portfolio

Clinical record & donor safety

What our clinical brand has done

10,000+

FMT & assays performed

Cumulative aFMT operations

5+

World medical records

Including the first global complete remission in Stage IVB pMMR/MSS colorectal cancer (Cureus 2024)

18–25

Donor age band (SDS)

Healthy university-age donors

120+

Donor medical screens

SDS donor-safety system

<2%

Donor acceptance rate

SDS donor-safety system

Evidence & consensus

Where the field stands

4

Expert consensus we contributed to or cited

See /evidence

6.80×

Endoscopic response vs. control in UC

From the UC consensus (2025) — 14 RCTs + ~600-case meta + ~15,000-case Chinese cohort

Source narratives and citations live on Evidence. For methodology questions, use Contact.